Immutep shares surge 27% as efti strategy narrows after TACTI-004 failure

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has outlined a substantially narrower development strategy for eftilagimod alfa, or efti, months after its pivotal TACTI-004 lung-cancer trial was discontinued for futility. Future registration-directed development is now intended to concentrate on PD-L1-negative head and neck squamous cell carcinoma and neoadjuvant soft-tissue sarcoma, while Immutep Limited undertakes a fresh 200-litre manufacturing run and continues investigating why TACTI-004 produced an unexpectedly weak outcome.

The market reaction was striking. Immutep Limited shares closed at A$0.056 on September 11, up 27.3% from A$0.044, with more than 45.8 million shares traded. The rally indicates that investors saw value in a defined clinical-development pathway after months of uncertainty, but the share price remains a fraction of where Immutep Limited traded before the Phase III setback earlier in 2026.

The critical scientific development is subtle. Immutep Limited’s ongoing root-cause investigation has identified structural and analytical differences between efti manufactured at the 200-litre scale used in earlier successful studies and the 2,000-litre-scale product used exclusively in TACTI-004. One cited difference involves N-glycan structure. The company considers those differences potentially relevant because immune activation in TACTI-004 differed markedly from previous trials, but it has not said that manufacturing scale has definitively been proven to cause the Phase III failure.

Why did Immutep Limited stop TACTI-004 after betting heavily on first-line lung cancer?

TACTI-004 had been designed as a global registrational Phase III study of efti combined with Merck & Co., Inc.’s Keytruda and chemotherapy in first-line advanced or metastatic non-small cell lung cancer. The study was expected to recruit approximately 756 patients across a large multinational network and was one of the clearest routes through which efti might have become a commercial oncology product.

That pathway collapsed when an independent data-monitoring review concluded that the trial had failed its planned futility test. Subsequent analysis showed an objective response rate of roughly 42.9% for the efti combination arm compared with approximately 55.1% for the control group in the evaluable population used for the analysis. The result was surprising partly because earlier efti studies had produced considerably more encouraging signals and because Immutep Limited had built the Phase III program on those earlier data.

The contrast with INSIGHT-003 remains central to the root-cause investigation. That smaller investigator-initiated study of efti, Keytruda and chemotherapy subsequently reported mature median overall survival of 30.9 months among 51 evaluable first-line non-squamous NSCLC patients. Immutep Limited has said immune-monitoring results from TACTI-004 displayed a different activation profile from those earlier studies.

The comparison nevertheless needs caution. INSIGHT-003 was small and single-arm, while TACTI-004 was a randomised Phase III trial designed to provide a much stronger test against a control group. Historical comparisons cannot override a failed controlled trial, which is why understanding the manufacturing and biological differences has become so important.

Could the 200-litre versus 2,000-litre manufacturing difference explain what happened?

Immutep Limited has now contracted a fresh 200-litre efti manufacturing run. The company previously produced 10 GMP batches at that scale for trials including TACTI-mel, TACTI-002 and INSIGHT-003, whereas TACTI-004 used material manufactured solely at 2,000-litre scale.

Scaling biological drug manufacturing is not always equivalent to simply using a larger vessel. Changes in process conditions can alter characteristics such as glycosylation, folding, aggregation or other product attributes capable of affecting biological activity. That is why structural differences identified after scale-up deserve investigation.

However, there is an important evidentiary gap between identifying a difference and establishing causation. Immutep Limited still needs to show that the 200-litre material consistently retains the activity associated with earlier clinical studies and that whatever changed at 2,000 litres was sufficiently meaningful to influence patient outcomes. Regulators and potential partners are likely to scrutinise comparability, manufacturing control and reproducibility before another registration-oriented program can proceed.

The latest plan therefore represents a reset rather than a resolution. Returning to the previously used scale reduces one variable, but future clinical data will ultimately determine whether efti can reproduce the biological and efficacy signals seen before TACTI-004.

Why is Immutep Limited prioritising head and neck cancer and soft-tissue sarcoma?

Head and neck squamous cell carcinoma offers Immutep Limited a potentially differentiated patient group. The company intends to focus on patients with a PD-L1 Combined Positive Score below 1, a population with limited immunotherapy options and where earlier efti data have suggested activity. Efti already holds United States Food and Drug Administration Fast Track designation in first-line head and neck cancer.

Soft-tissue sarcoma provides a second, biologically different route. Efti has been evaluated with radiotherapy and Keytruda before surgery in the investigator-led Phase II EFTISARC-NEO study, which met its primary endpoint. The FDA granted efti Orphan Drug Designation for soft-tissue sarcoma in April 2026, potentially providing development incentives and seven years of United States market exclusivity after approval if the regulatory requirements are ultimately met.

Both indications are smaller than first-line non-small cell lung cancer, but that can actually support a staged development strategy. Smaller, biomarker-defined or rare-disease settings may require less capital and offer clearer patient selection than a huge all-comers lung-cancer trial.

Immutep Limited is targeting the second half of calendar 2027 for the next studies, although timing remains dependent on trial design, regulatory discussions, manufacturing, partnering and available resources. That means investors face a relatively long interval before a fresh registration-directed efficacy readout is likely.

Does Immutep Limited have enough cash to fund the clinical reset?

Immutep Limited reported approximately A$68.87 million of cash, cash equivalents and term deposits at June 30, 2026. Following the TACTI-004 discontinuation, management introduced cost reductions and estimated that available resources could extend the runway into the first half of calendar 2028.

The failed trial also affected Immutep Limited’s commercial agreement with Dr. Reddy’s Laboratories Limited. Under a licensing deal signed in late 2025, Dr. Reddy’s received exclusive rights to develop and commercialise efti across numerous markets outside North America, Europe, Japan and Greater China. Immutep Limited originally received US$20 million upfront and remains eligible for as much as US$349.5 million of potential development, regulatory and commercial milestones plus royalties, while retaining global manufacturing rights.

TACTI-004’s discontinuation triggered a US$10 million payment obligation back to Dr. Reddy’s Laboratories under the agreement. That reduced some of the financial protection created by the original upfront payment, although Dr. Reddy’s has been consulted on the revised efti strategy and is supportive of the proposed direction, according to Immutep Limited.

This financial context makes focus essential. Immutep Limited cannot afford to recreate the cost profile of a massive global Phase III lung-cancer study before it has rebuilt confidence in manufacturing and efficacy.

What should investors require before treating the Immutep Limited recovery as proven?

The September 11 share-price rally reflects relief and renewed optionality, not clinical validation. Three milestones now matter more than the 27% one-day market move.

First, Immutep Limited needs to complete the TACTI-004 root-cause investigation and establish whether the manufacturing differences are genuinely linked to the altered immune profile. Second, the new 200-litre product needs to satisfy analytical and regulatory requirements. Third, future HNSCC and soft-tissue sarcoma trials need to reproduce compelling biological and clinical activity.

There is still a broader scientific case behind efti. A pooled analysis of five previous studies involving 592 patients found that efti plus standard therapy increased circulating lymphocyte counts, with biological responders showing a median overall-survival advantage of 7.7 months over non-responders. That analysis supports the mechanism but cannot erase the contradictory Phase III result.

The investment thesis has therefore changed dramatically. Immutep Limited is no longer a late-stage biotechnology company marching predictably toward a large lung-cancer opportunity. It is a cash-backed clinical developer attempting to determine why its pivotal trial diverged from earlier evidence and whether two more targeted indications can restore a viable registration pathway.